GH Research PLC (GHRS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Florian Schonharting M.Sc. (Econ)
|
Co-Founder & Non-Executive Chairman of the Board | -- | -- | 1969 |
|
Dr. Velichka Valcheva M.D., M.Sc.
|
Chief Executive Officer | -- | -- | 1975 |
|
Mr. Magnus Halle
|
Co-Founder & MD of Ireland | -- | -- | 1997 |
|
Ms. Julie Ryan F.C.A.
|
Vice President of Finance | -- | -- | 1986 |
|
Mr. Aaron Cameron M.B.A.
|
Chief Operating Officer | -- | -- | 1985 |
GH Research PLC
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 73
Description
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
GH Research PLC Earnings Date
Recent Events
May 15, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
